Tissue assays

Within EUbOPEN, our aim is to develop open access cell assay protocols and data from well-characterised human disease tissue and blood-derived assays to profile chemical probes and chemogenomic libraries, guiding identification of biomarkers and novel targets to drive drug discovery. To this end we develop human tissue and blood-derived assays within areas of high medical need in inflammatory diseases, fibrosis, oncology and neurodegenerative diseases. The current network of collaborations consists of hospitals, research institutes and universities in Toronto and Montreal (Canada), Frankfurt (Germany) and Stockholm (Sweden).

EUbOPEN Tissue Assay data sets:

Colorectal cancer

Colorectal cancer

Development of a 384-well assay in CRC PDTOs to study pharmacologic dose-responses
Identification of compartment-specific drug sensitivities in CRC organoid-stroma co-cultures (dual luciferase assay)
Image-based profiling of drug vulnerabilities in CRC organoids
Optimized Dual-Glo Assay to identify co-cultureinduced drug vulnerabilities in 3D CRC models
Pharmacologic enhancement of CAR-T cell function in CRC organoid co-cultures
Targeting of CAF-induced therapy resistance in CRC organoid-stroma co-cultures
Therapy re-sensitization of drug resistant organoids
Viability screening in matched tumor and normal organoids from colorectal cancer patients
Inflammatory bowel disease

Inflammatory bowel disease

Patient-derived organoids-fibroblasts co-culture system to assess the effect of chemical probes on individual organoids size
Patient-derived organoids-fibroblasts co-culture system to assess the effect of chemical probes on organoids growth kinetics
Patient-derived organoids-fibroblasts co-culture system to assess the effect of chemical probes on organoids total area
Patient-derived organoids-fibroblasts co-culture system to assess the effect of chemical probes on organoids viability
Liver fibrosis

Liver fibrosis

Hepatotoxicity screening of Donated Chemical Probes
Patient-derived NASH model to assess antisteatosis effects of chemical probes
Patient-derived NASH model to assess fibrosis effects of chemical probes
Patient-derived NASH model to assess inflammatory effects of chemical probes
Patient-derived NASH model to assess the effects of chemical probes on DNA damage response
Patient-derived NASH model to assess the effects of chemical probes on hepatocyte regeneration
Multiple sclerosis

Multiple sclerosis

Cytokine secretion screen in isolated B cell assay
Toxicity screen in isolated B cell assay
Toxicity screen in purified B cell assay